Dr Y. Colson (Boston, Mass). You have nicely investigated the potential role of MMP-12 in lung cancer progression, mainly invasion, and you have postulated a role for it as a therapeutic target. You have shown roughly 3 aspects of what you have investigated, quite elegantly, actually. First is in characterizing MMP-12 expression and localization in tissue samples, and in gene array databases you have ubiquitous expression in NSCLC with the exception of the bronchoalveolar, and the association of MMP-12 mRNA in tumors with reduced survival.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

Authors: Guo N, Zhao Y, Zhang W, Li S, Li S, Yu J Abstract MicroRNAs (miRNAs) may serve important roles in the regulation of human non-small cell lung cancer (NSCLC) cell growth and apoptosis. To the best of our knowledge, the present study was the first to explore the role of miRNA-133a/epidermal growth factor receptor (EGFR) in regulating NSCLC cell growth and apoptosis via the AKT/extracellular signal-regulated kinase (ERK) signaling pathway. It was determined that miRNA-133a expression was lower in NSCLC tissue than in the adjacent mucosae. Additionally, EGFR expression in the NSCLC tissue was higher compared w...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Lu H, Wu S, Chen H, Huang Y, Qiu G, Liu L, Li Y Abstract Effect of crizotinib on apoptosis of lung cancer cells was investigated. Human non-small cell lung adenocarcinoma H2228 cells were cultured in the presence of 0, 20, 40, 80, 160 and 320 nmol/l of crizotinib for 3 days, respectively. The inhibition rate of cell proliferation was measured by MTT assay, and half maximal inhibitory concentration (IC50) was calculated. Cell apoptosis was detected by flow cytometry. Transwell assay was performed to detect cell migration. Expression of Janus protein tyrosine kinase (JAK) and signal transducer and activator ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, the present data identified miR-339-5p as a novel LA suppressor which exerted its functions partly by negatively regulating BCL6. PMID: 30333862 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG Abstract Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In this study, we systematically analysed immunoreactivity for IL-17A, IL-17E and IL-17F and their relevant receptors in the lung sections from non-small cell lung cancer (NSCLC) and normal control. Immunoreactivity for IL-17A, IL-17F, IL-17RA and IL- 17RC, but not IL-17RB was significantly elevated in NSCLC compared with controls, while IL-17E was reduced. The median numbers of infiltrating lymphocytes and neutrophils and global macrophage (CD68) immunoreactivity of phagocytes were also elevated in NSCLC compared with control tissue sections. Furthermore, correlation between the expression of IL-17A and its receptors IL-1...
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
Authors: Okimoto T, Tsubata Y, Hotta T, Hamaguchi M, Nakao M, Hamaguchi SI, Hamada A, Isobe T Abstract The central nervous system is a common site of relapse in patients receiving crizotinib, which is presumed to be associated with the low concentration of crizotinib in the cerebrospinal fluid (CSF). Our patient received surgical treatment for anaplastic lymphoma kinase-positive stage IIA lung adenocarcinoma. His cancer recurred with brain metastases and carcinomatous meningitis. We started whole-brain radiation therapy (WBRT) and subsequently administered crizotinib. The concentration of crizotinib on day 15 in th...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Lung cancer represents the most common cause of brain dissemination. Brain metastases are present at diagnosis in approximately 25% of patients with advanced non-small lung cancer (NSCLC) and may develop in a higher proportion during the course of the disease [1]. In two-thirds of lung cancer patients brain metastases are multiple, and in one third singular [2]. The incidence of leptomeningeal carcinomatosis in NSCLC ranges between 5 to 10% [3]. With better extracranial control resulting from the progress in systemic therapy, brain involvement is diagnosed more often.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research
ConclusionsGenerally, superior vena cava syndrome is the result of extrinsic compression of the superior vena cava by tumor. Our patient ’s case represents the development of superior vena cava syndrome after an excellent response of tumor with near-complete tumor response. We suspect chemoradiation therapy as a potential etiology for the precipitation of the superior vena cava syndrome, which is currently not well reported in the medical literature.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Immune checkpoint inhibitors are a new class of anticancer drugs recently approved by the US Food and Drug Administration (FDA) for the treatment of various malignancies. Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein-1 (PD-1) receptor and blocks its interaction with programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2). Pembrolizumab was first approved by the FDA in 2014 for the treatment of advanced melanoma and is currently approved for use in non-small cell lung cancer and several other neoplasms.
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research
Source: OncoImmunology - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Databases & Libraries | Genetics | Heart | Lung Cancer | Non-Small Cell Lung Cancer